The story of Brian Overstreet’s latest company begins with a long walk in Palo Alto and a question that refused to shrink. It was the summer of 2023. Overstreet and Travis May kept circling the same puzzle: after more than twenty years of policy, investment and earnest effort, why had value-based care struggled to scale?
The easy answers were familiar. Healthcare is complicated. Incentives are misaligned. Old systems resist new behavior. Overstreet and May focused lower in the stack, where ambition becomes a spreadsheet and then a payment. Risk-based contracts can be hard to design, their data arrives in fragments, their calculations require specialist judgment, and their performance is often clearest only after the moment when an operator could have changed it.
That diagnosis became Arbital Health. Overstreet, its co-founder, president and CEO, describes the company as infrastructure for the people on both sides of those contracts. The product brings contract terms, claims data, actuarial models, forecasts and eventual adjudication into a common environment. It is an attempt to turn an argument over numbers into a shared view of the numbers.
“Risk contracts demand proactive, forward-looking insight, not retrospective reporting.”Brian M. Overstreet, July 2026
01 / The recurring patternA career built around the dense part
Overstreet did not set out to become a healthcare-data founder. At the University of California, Berkeley, he studied political science because he thought he might become a lawyer. The attraction did not last. He realized quickly that the profession was not for him, but the degree left behind a useful discipline: reading carefully, writing clearly and sorting competing claims.
After graduation, he spent a few years in investment banking. Then the internet began changing how research could be distributed. Overstreet saw that a data product placed online could travel farther and acquire customers faster than a traditional research service. He co-founded Sagient Research Systems in 1999 and led it as president and CEO for a decade, later becoming chairman. Its products served financial institutions and healthcare customers, including a drug-development database and research used by investment firms, pharmaceutical companies, universities and public agencies.
The Overstreet operating pattern
Informa acquired Sagient in May 2012. By then, Overstreet had already encountered another dataset worth cleaning: public reports related to drug safety. The company that became Advera Health Analytics spent more than eighteen months turning difficult records into a clean, queryable system, then built analytics and workflow tools around them. TriNetX acquired Advera in 2022.
Across those two exits, the surface markets changed while the underlying method stayed recognizable. Begin where the data is valuable but awkward. Do the patient work of normalization. Add software, judgment and distribution. Build a recurring product that customers can use rather than a report they merely receive.
02 / The founder filterThree reasons to start again
A third startup was not automatic. Overstreet has written that, after two exits, he was not looking to return lightly. Years of company-building had made the cost legible: a founder gives a problem an enormous portion of his attention. Before saying yes again, he set three conditions.
The people
Work with colleagues he regarded as unusually capable.
The problem
Take on a large, complicated data challenge.
The change
Create a credible path to system-level impact.
Arbital met the filter. Its founding team paired Overstreet’s product and operating experience with May’s work in healthcare data and investing. In January 2024, the young company announced a $10 million Series A and acquired Santa Barbara Actuaries, bringing contract-design and adjudication expertise into the business from the start. The structure mattered. Arbital would not ask software alone to impersonate actuarial judgment; it would use actuaries to shape the software and work alongside it.
That combination also reveals the business model. Services can solve the customer’s immediate contract problem. The platform can capture repeated logic, centralize data and make each subsequent analysis more operational. The result is less like buying a one-time answer and more like installing a continuously updated scoreboard.
03 / A shared scoreboardWhere the trust has to live
Risk contracts make an unusually demanding software brief. A provider and a payer may agree on the aspiration and still disagree on attribution, benchmarks, timing, adjustments or the calculation of savings. Each clause can alter the final settlement. If both parties work from different data and report on different schedules, operational uncertainty compounds into financial uncertainty.
Overstreet’s phrase for the intended role is a “neutral adjudicator.” It is deliberately institutional language. Arbital is trying to occupy the middle: neither party’s private spreadsheet, but a system that makes contract logic traceable and performance visible while there is still time to act. The product thesis is that trust can be partly architectural - shared definitions, inspectable calculations and a record of how the score was produced.
Company-reported figures published in October 2025.
Investors have backed the attempt. In July 2025, Arbital announced a $31 million Series B led by Valtruis, with Transformation Capital, Shaper Capital and Healthy Ventures participating. Combined with the earlier Series A, the announced equity rounds totaled $41 million. The capital funded a company that was hiring across actuarial, engineering and commercial teams while adding products for different stages of the contract cycle.
Announced institutional rounds
04 / From platform to accessThe product moves outward
The releases since then map an effort to make specialized analysis more immediate. Merlin AI, introduced in October 2025, gave platform users a conversational interface for risk-contract questions. ATLAS, announced in June 2026, added modeling for organizations evaluating a new federal accountable-care structure. A month later, Arbital launched Flex, a self-serve product for teams that may not have a full implementation, an existing risk contract or a large internal actuarial department.
Flex matters because it moves the starting line. A provider can upload its own data, assess a population, compare performance with benchmarks and question the results in natural language before committing to risk. Overstreet framed the release around speed: insight in days rather than a consulting or implementation cycle measured in months. The product carries the founding thesis into a smaller package. Better contract decisions begin before the signature.
There is also a community layer to the strategy. Arbital’s first Nashville summit gathered more than 100 leaders in 2025. The second brought more than 150 in March 2026. Overstreet used his recap to test the company’s work against the market’s concerns. Attendees believed value-based models could work, he wrote, but struggled to prove near-term financial impact. They wanted clearer economics for interventions. They were also becoming more skeptical about whether every use of AI actually lowers costs.
“We need durable partnerships, not transactional ones.”Brian M. Overstreet, after Arbital’s 2025 summit
The skepticism is useful. Arbital sells AI, but Overstreet’s public argument rarely begins with a model. It begins with contract terms, clean data and actuarial logic. AI is presented as an interface and an accelerator, not a substitute for the work that makes the answer defensible. That posture fits a founder whose first internet insight was about distribution but whose companies survived by doing the unglamorous work underneath it.
05 / The human marginA label made from three names
The career has a playful footnote in wine. Brian and his wife, Kerith Overstreet, launched Bruliam Wines with a 2008 Pinot Noir. The label’s name is an amalgam of their three children’s names, a family puzzle presented as a brand. Contemporary coverage described the pair as enthusiastic newcomers having conspicuous fun with the project. Profits were directed to the Overstreet Family Foundation and its charitable beneficiaries.
A family word hidden in plain sight.
Bruliam combined the names of the Overstreets’ three children. The tiny wine business turned a private joke into a public label and its proceeds into giving.
The winery sits outside the neat enterprise-software narrative, which is why it belongs in the story. A person can enjoy the puzzle of a name, make a bottle with his family and still spend Monday thinking about actuarial calculations. Overstreet’s public persona is serious about systems but not sealed inside them.
His most revealing career comment may still be the one about political science. The degree looked indirect until it did not. Reading and writing became tools for a data-focused life. Banking exposed information markets. Research became software. Two acquisitions created the freedom to be selective. A long walk supplied the next question.
Now the question is whether Arbital can become the neutral layer its founders imagined. Shared ledgers only work when enough participants accept the same rules, and enterprise infrastructure is earned contract by contract. Overstreet’s wager is precise: value-based care will move faster when its economics are visible, its calculations are traceable and both sides can see the score before the game is over.